Hangzhou Tigermed Consulting logo

Hangzhou Tigermed Consulting(SEHK) 3347

Market CapHK$35.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-61%
5 Year-72%
1 Year-5%
1 Month-4%
HK$41.88
+0.92%
+0.38Today
Hangzhou Tigermed Consulting last closing stock price
MetricPriceDate
Last closeHKD 41.882026-10-15
Hangzhou Tigermed Consulting stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.29%HKD 44.222026-10-08
1 month-4.16%HKD 43.702026-09-15
3 month+14.11%HKD 36.702026-07-17
Year to date-1.55%HKD 42.542025-12-31
1 year-4.56%HKD 43.882025-10-15
3 year-3.06%HKD 43.202023-10-16
5 year-72.45%HKD 152.002021-10-15
Since inception-61.45%HKD 107.662020-08-07

Hangzhou Tigermed Consulting Financials at a Glance

Market Cap

HK$35.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥7.28B

Net Income (TTM)

CN¥93.15M

EPS (TTM)

HK$0.07

P/E Ratio

630.40

Dividend

HK$0.14

Beta (Volatility)

-0.03 (Low)

Price

HK$41.88

Volume

377,000

Open

HK$41.12

Previous Close

HK$41.50

Daily Range

HK$41.08 - HK$42.70

52-Week Range

HK$24.55 - HK$60.60

Estimated Earnings Date

Oct 30, 2026

3347 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd. is a leading provider of clinical research services, specializing in the development of pharmaceutical and health-related products. Founded in 2004 and headquartered in Hangzhou, China, the company offers a comprehensive range of services, including clinical trial management and data analysis.

Products and Services
  • Clinical trial management for phases I to IV
  • Data management and analysis services
  • Regulatory support for clinical trial registration
Growth Outlook
  • Revenue increased to CNY 1.90 billion in Q2 2026
  • Operating income improved to CNY 223 million in Q2 2026
  • Strong demand for clinical research services supports future growth
Financial Highlights
  • Net income of CNY -460 million in Q2 2026
  • Gross profit margin of 26.7% in Q2 2026
  • Current ratio of 2.49 indicates strong liquidity position
Hangzhou Tigermed Consulting Co., Ltd. operates in the biotechnology sector, focusing on clinical research services that are essential for the pharmaceutical industry. The company has demonstrated resilience and adaptability in a competitive market, with a notable increase in revenue in the most recent quarter. Despite reporting a net loss, the operating income reflects a positive trend, indicating effective cost management and operational efficiency. The company's strong liquidity, as evidenced by a current ratio of 2.49, positions it well to navigate financial challenges and invest in future growth opportunities. The demand for clinical research services continues to rise, driven by the increasing complexity of drug development and regulatory requirements. This trend is expected to bolster the company's growth trajectory in the coming years. Investors may find Hangzhou Tigermed Consulting Co., Ltd. an intriguing opportunity, given its established market presence and the ongoing expansion of the biotechnology sector. The company's commitment to providing high-quality clinical research services positions it favorably for sustained growth and profitability.
AI Generated • Sep 29, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

11,130

CEO

Zeng Yu Wen

Website

www.tigermed.net

Headquarters

Hangzhou, ZH 310051, CN

3347 Financials

Key Financial Metrics (TTM)

Gross Margin

25.85%

Operating Margin

16.39%

Net Income Margin

1.25%

Return on Equity

0.44%

Return on Capital

4.50%

Return on Assets

0.33%

Earnings Yield

0.16%

Dividend Yield

0.34%

Payout Ratio

95.33%

Stock Overview

Market Cap

HK$35.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

834.17M

Volume

377.00K

Avg. Volume

1.71M

Financials (TTM)

Gross Profit

CN¥1.88B

Operating Income

CN¥1.19B

EBITDA

CN¥1.92B

Operating Cash Flow

CN¥1.42B

Capital Expenditure

-CN¥221.64M

Free Cash Flow

CN¥1.20B

Cash & ST Invst.

CN¥2.15B

Total Debt

CN¥2.35B

Hangzhou Tigermed Consulting Performance Analysis

Hangzhou Tigermed Consulting annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 8,217,861,44631.2%
20232023-12-31CNY 8,135,206,277-1.0%
20242024-12-31CNY 7,138,599,853-12.3%
20252025-12-31CNY 7,390,609,6203.5%
Hangzhou Tigermed Consulting sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.3%
Q42025-12-311.8%
Q12026-03-31-0.3%
Q22026-06-305.4%
Hangzhou Tigermed Consulting annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 2.70-32.2%
20232023-12-31CNY 2.59-4.1%
20242024-12-31CNY 0.51-80.4%
20252025-12-31CNY 1.13121.5%
Hangzhou Tigermed Consulting sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30196.0%
Q42025-12-31-120.3%
Q12026-03-31140.0%
Q22026-06-30-1016.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥1.90B

+12.6%

Gross Profit

CN¥507.10M

-0.2%

Gross Margin

26.72%

N/A

Market Cap

HK$35.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$3.17M

N/A

Employees

11,130

N/A

Net Income

-CN¥460.24M

-311.2%

EBITDA

CN¥313.32M

-22.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥2.15B

+18.1%

Total Debt

CN¥2.35B

-1.5%

Accounts Receivable

CN¥4.20B

+1.0%

Inventory

CN¥65.61M

+50.4%

Long Term Debt

CN¥1.93B

+105.3%

Short Term Debt

CN¥413.24M

-71.3%

Return on Assets

0.33%

N/A

Return on Invested Capital

4.74%

N/A

Free Cash Flow

CN¥191.11M

+21.0%

Operating Cash Flow

CN¥247.54M

+17.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About 3347

What is the current price of Hangzhou Tigermed Consulting?

Hangzhou Tigermed Consulting is trading at HK$41.88 per share.

What is the 52-week range for Hangzhou Tigermed Consulting?

Over the past 52 weeks, Hangzhou Tigermed Consulting has traded between HK$24.55 and HK$60.60.

How much debt does Hangzhou Tigermed Consulting have?

As of the most recent reporting period, Hangzhou Tigermed Consulting reported total debt of CN¥2.71B.

How much cash does Hangzhou Tigermed Consulting have on hand?

Hangzhou Tigermed Consulting reported CN¥2.37B in cash and cash equivalents in its most recent financial results.

What is Hangzhou Tigermed Consulting’s dividend yield?

Hangzhou Tigermed Consulting currently has a dividend yield of 0.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services